David J Taber1,2, Zemin Su3, James N Fleming1,4, John W McGillicuddy1, Maria A Posadas-Salas5, Frank A Treiber6, Derek Dubay1, Titte R Srinivas7, Patrick D Mauldin3, William P Moran3, Prabhakar K Baliga8. 1. Division of Transplant Surgery, Medical University of South Carolina, Charleston, SC. 2. Department of Pharmacy Services, Ralph H Johnson VAMC, Charleston, SC. 3. Division of General Internal Medicine, Medical University of South Carolina, Charleston, SC. 4. Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC. 5. Division of Nephrology, Medical University of South Carolina, Charleston, SC. 6. College of Nursing, Medical University of South Carolina, Charleston, SC. 7. Division of Nephrology, Intermountain Healthcare, Salt Lake City, UT. 8. Department of Surgery, Medical University of South Carolina, Charleston, SC.
Abstract
BACKGROUND: Low tacrolimus concentrations have been associated with higher risk of acute rejection, particularly within African American (AA) kidney transplant recipients; little is known about intrapatient tacrolimus variabilities impact on racial disparities. METHODS: Ten year, single-center, longitudinal cohort study of kidney recipients. Intrapatient tacrolimus variability was assessed using the coefficient of variation (CV) measured between 1 month posttransplant and the clinical event, with a comparable period assessed in those without events. Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were excluded. Multivariable Cox regression models were used to analyze data. RESULTS: One thousand four hundred eleven recipients were included (54.4% AA) with 39 521 concentrations used to assess intrapatient tacrolimus CV. Overall, intrapatient tacrolimus CV was higher in AAs versus non-AAs (39.9 ± 19.8 % vs 34.8 ± 15.8% P < 0.001). Tacrolimus variability was a significant risk factor for deleterious clinical outcomes. A 10% increase in tacrolimus CV augmented the risk of acute rejection by 20% (adjusted hazard ratio, 1.20, 1.13-1.28; P < 0.001) and the risk of graft loss by 30% (adjusted hazard ratio, 1.30, 1.23-1.37; P < 0.001), with significant effect modification by race for acute rejection, but not graft loss. High tacrolimus variability (CV >40%) was a significant explanatory variable for disparities in AAs; the crude relative risk of acute rejection in AAs was reduced by 46% when including tacrolimus variability in modeling and reduced by 40% for graft loss. CONCLUSIONS: These data demonstrate that intrapatient tacrolimus variability is strongly associated with acute rejection in AAs and graft loss in all patients. Tacrolimus variability is a significant explanatory variable for disparities in AA recipients.
BACKGROUND: Low tacrolimus concentrations have been associated with higher risk of acute rejection, particularly within African American (AA) kidney transplant recipients; little is known about intrapatient tacrolimus variabilities impact on racial disparities. METHODS: Ten year, single-center, longitudinal cohort study of kidney recipients. Intrapatient tacrolimus variability was assessed using the coefficient of variation (CV) measured between 1 month posttransplant and the clinical event, with a comparable period assessed in those without events. Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were excluded. Multivariable Cox regression models were used to analyze data. RESULTS: One thousand four hundred eleven recipients were included (54.4% AA) with 39 521 concentrations used to assess intrapatient tacrolimus CV. Overall, intrapatient tacrolimus CV was higher in AAs versus non-AAs (39.9 ± 19.8 % vs 34.8 ± 15.8% P < 0.001). Tacrolimus variability was a significant risk factor for deleterious clinical outcomes. A 10% increase in tacrolimus CV augmented the risk of acute rejection by 20% (adjusted hazard ratio, 1.20, 1.13-1.28; P < 0.001) and the risk of graft loss by 30% (adjusted hazard ratio, 1.30, 1.23-1.37; P < 0.001), with significant effect modification by race for acute rejection, but not graft loss. High tacrolimus variability (CV >40%) was a significant explanatory variable for disparities in AAs; the crude relative risk of acute rejection in AAs was reduced by 46% when including tacrolimus variability in modeling and reduced by 40% for graft loss. CONCLUSIONS: These data demonstrate that intrapatient tacrolimus variability is strongly associated with acute rejection in AAs and graft loss in all patients. Tacrolimus variability is a significant explanatory variable for disparities in AA recipients.
Authors: Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson Journal: Br J Clin Pharmacol Date: 2011-12 Impact factor: 4.335
Authors: Lennaert C P Borra; Joke I Roodnat; Judith A Kal; Ron A A Mathot; Willem Weimar; Teun van Gelder Journal: Nephrol Dial Transplant Date: 2010-02-26 Impact factor: 5.992
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; D E Stewart; W S Cherikh; J L Wainright; A Kucheryavaya; M Woodbury; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: David J Taber; Mulugeta G Gebregziabher; Titte R Srinivas; Kenneth D Chavin; Prabhakar K Baliga; Leonard E Egede Journal: Pharmacotherapy Date: 2015-05-23 Impact factor: 4.705
Authors: Henry R Whalen; Julie A Glen; Victoria Harkins; Katherine K Stevens; Alan G Jardine; Colin C Geddes; Marc J Clancy Journal: Transplantation Date: 2017-02 Impact factor: 4.939
Authors: Stephan R Seibert; David P Schladt; Baolin Wu; Weihua Guan; Casey Dorr; Rory P Remmel; Arthur J Matas; Roslyn B Mannon; Ajay K Israni; William S Oetting; Pamala A Jacobson Journal: Clin Transplant Date: 2018-10-31 Impact factor: 2.863
Authors: David J Taber; Zemin Su; James N Fleming; Nicole A Pilch; Thomas Morinelli; Patrick Mauldin; Derek Dubay Journal: Transpl Int Date: 2018-09-16 Impact factor: 3.782
Authors: Jennifer F Wu; Amutha Muthusamy; Gabriel A Al-Ghalith; Dan Knights; Bin Guo; Baolin Wu; Rory P Remmel; David P Schladt; Maria-Luisa Alegre; William S Oetting; Pamala A Jacobson; Ajay K Israni Journal: Clin Transplant Date: 2018-11-18 Impact factor: 2.863
Authors: Marina Serper; Daniela P Ladner; Laura M Curtis; Sumi S Nair; Scott I Hur; Mary J Kwasny; Bing Ho; John Friedewald; Peter P Reese; Michael M I Abecassis; Michael S Wolf Journal: Contemp Clin Trials Date: 2021-01-27 Impact factor: 2.226
Authors: Dana R Pierce; Patricia West-Thielke; Zahraa Hajjiri; Sujata Gaitonde; Ivo Tzvetanov; Enrico Benedetti; Alicia B Lichvar Journal: Transplant Direct Date: 2021-05-18